Literature DB >> 10936878

LDL receptor-related protein (LRP) in Alzheimer's disease: towards a unified theory of pathogenesis.

E Van Uden1, D E Kang, E H Koo, E Masliah.   

Abstract

To date, mutations in three genes, beta-amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2), have been found to be causally related to familial Alzheimer's disease (AD). In addition, polymorphisms in three other genes (among others), apolipoprotein E (apoE), alpha2-macroglobulin (alpham), and the low density lipoprotein receptor-related protein (LRP), are implicated to contribute to AD pathogenesis. Interestingly, the encoded gene products are all functionally related in various ways to LRP. Specifically apoE, alpha2m, secreted APP, and amyloid beta-protein (Abeta) complexed to either apoE or alpha2m are ligands of LRP. Furthermore, over-expression of presenilin 1 results in decreased expression of LRP. Since levels of many LRP ligands are increased in Alzheimer's disease and LRP and its ligands are present in senile plaques, decreased LRP function may be a central component in AD pathogenesis. This review explores the current knowledge of LRP in AD and its relationship to the other known AD susceptibility markers. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10936878     DOI: 10.1002/1097-0029(20000815)50:4<268::AID-JEMT3>3.0.CO;2-1

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  14 in total

Review 1.  Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease.

Authors:  Xianlin Han
Journal:  Biochim Biophys Acta       Date:  2010-02-01

Review 2.  Getting to the Heart of Alzheimer Disease.

Authors:  Joshua M Tublin; Jeremy M Adelstein; Federica Del Monte; Colin K Combs; Loren E Wold
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

Review 3.  Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: a tale of shotgun lipidomics.

Authors:  Xianlin Han
Journal:  J Neurochem       Date:  2007-11       Impact factor: 5.372

Review 4.  The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease.

Authors:  Xianlin Han
Journal:  Mol Neurobiol       Date:  2010-01-07       Impact factor: 5.590

5.  APP independent and dependent effects on neurite outgrowth are modulated by the receptor associated protein (RAP).

Authors:  Andrew J Billnitzer; Irina Barskaya; Cailing Yin; Ruth G Perez
Journal:  J Neurochem       Date:  2012-11-15       Impact factor: 5.372

6.  Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking.

Authors:  Rodrigo A Fuentealba; Qiang Liu; Juan Zhang; Takahisa Kanekiyo; Xiaoyan Hu; Jin-Moo Lee; Mary Jo LaDu; Guojun Bu
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

7.  Immunocytochemical traits of type IV fibrocytes and their possible relations to cochlear function and pathology.

Authors:  Joe C Adams
Journal:  J Assoc Res Otolaryngol       Date:  2009-03-10

8.  Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease.

Authors:  Hua Cheng; Yunhua Zhou; David M Holtzman; Xianlin Han
Journal:  Neurobiol Aging       Date:  2008-08-31       Impact factor: 4.673

Review 9.  Leptin: a novel therapeutic strategy for Alzheimer's disease.

Authors:  Nikolaos Tezapsidis; Jane M Johnston; Mark A Smith; J Wesson Ashford; Gemma Casadesus; Nikolaos K Robakis; Benjamin Wolozin; George Perry; Xiongwei Zhu; Steven J Greco; Sraboni Sarkar
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein.

Authors:  Celina V Zerbinatti; David F Wozniak; John Cirrito; Judy A Cam; Hiroshi Osaka; Kelly R Bales; Min Zhuo; Steven M Paul; David M Holtzman; Guojun Bu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.